美國(guó)人糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株

簡(jiǎn)要描述：美國(guó)人Glucocorticoid糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株（線粒體表達(dá)）
美國(guó)人糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株
美國(guó)PrimCells誘導(dǎo)性穩(wěn)定細(xì)胞株： PrimCells建立的*的誘導(dǎo)性細(xì)胞高效開發(fā)系統(tǒng)，能在極短時(shí)間內(nèi)篩選出低泄漏，高誘導(dǎo)性的穩(wěn)定細(xì)胞株，成功開發(fā)出一系列核受體誘導(dǎo)表達(dá)的穩(wěn)定細(xì)胞

產(chǎn)品型號(hào)：CLHKGR02
廠商性質(zhì)：生產(chǎn)廠家
更新時(shí)間：2025-07-08
訪問(wèn) 量：2259

產(chǎn)品咨詢聯(lián)系我們

產(chǎn)品分類

Product Category

細(xì)胞庫(kù)

細(xì)胞原代牛、狗、雞、鴨、魚原代細(xì)胞羊原代細(xì)胞豬原代細(xì)胞兔原代細(xì)胞小鼠原代細(xì)胞大鼠原代細(xì)胞人原代細(xì)胞培養(yǎng)基原代細(xì)胞凍存液 ATCC 人乳腺癌豬正常細(xì)胞豬睪丸細(xì)胞系人膠質(zhì)瘤細(xì)胞人成骨細(xì)胞人永生化肝細(xì)胞人肝癌細(xì)胞人卵巢癌細(xì)胞人結(jié)直腸腺癌人經(jīng)典小細(xì)胞肺癌細(xì)胞人小細(xì)胞肺癌細(xì)胞人結(jié)直腸腺癌細(xì)胞人鼻腔上皮細(xì)胞中國(guó)倉(cāng)鼠卵巢懸浮細(xì)胞嗜性逆轉(zhuǎn)錄病毒包裝穩(wěn)定細(xì)胞株小鼠神經(jīng)細(xì)胞瘤人眼脈洛膜黑色素瘤 PT67 逆轉(zhuǎn)錄酶病毒包裝細(xì)胞鴨子胚胎成纖維細(xì)胞豬腎細(xì)胞系昆蟲細(xì)胞貓腎細(xì)胞恒河猴胚腎細(xì)胞倉(cāng)鼠卵巢細(xì)胞負(fù)鼠腎細(xì)胞倉(cāng)鼠肺細(xì)胞果蠅胚胎細(xì)胞家貓肺成纖維樣細(xì)胞雞胚細(xì)胞豚鼠心肌來(lái)源細(xì)胞豚鼠肺成纖維樣細(xì)胞豚鼠皮膚成纖維樣細(xì)胞狗腎細(xì)胞非洲綠猴胚胎腎上皮細(xì)胞猴胚胎腎上皮細(xì)胞長(zhǎng)臂猿淋巴瘤新生牛眼囊成纖維細(xì)胞黑化大家鼠肺成纖維樣細(xì)胞俄勒岡地鼠細(xì)胞家兔皮膚成纖維樣細(xì)胞昆蟲卵巢細(xì)胞人胸膜瘤細(xì)胞非洲綠猴腎細(xì)胞 VERO 衍生株（SVP）白化金黃地鼠肺成纖維樣細(xì)胞黃胸鼠肺成纖維樣細(xì)胞白鰱尾鰭細(xì)胞蝙蝠肺細(xì)胞草魚腎細(xì)胞系大黃魚腎細(xì)胞猴腎細(xì)胞系犬腎細(xì)胞系人結(jié)腸直腸腺癌豬肺泡巨噬細(xì)胞 PFHSA05（TLL2）人重組特洛德樣蛋白因子 PFHSA04 （BMP1）人重組骨誘導(dǎo)因子人乳腺癌細(xì)胞結(jié)腸癌細(xì)胞成纖維細(xì)胞人胚腎細(xì)胞動(dòng)物卵巢細(xì)胞動(dòng)物胚胎細(xì)胞動(dòng)物肺細(xì)胞肋骨來(lái)源細(xì)胞成纖維樣細(xì)胞動(dòng)物上皮細(xì)胞動(dòng)物肝臟細(xì)胞可誘導(dǎo)表達(dá)穩(wěn)定細(xì)胞株動(dòng)物氣管細(xì)胞動(dòng)物腎細(xì)胞動(dòng)物巨噬細(xì)胞人正常細(xì)胞人腫瘤細(xì)胞、癌細(xì)胞小鼠正常細(xì)胞小鼠腫瘤細(xì)胞、癌細(xì)胞大鼠正常細(xì)胞大鼠腫瘤細(xì)胞其它動(dòng)物細(xì)胞查看全部產(chǎn)品

相關(guān)文章

詳細(xì)介紹

美國(guó)人Glucocorticoid糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株（線粒體表達(dá)）

美國(guó)PrimCells誘導(dǎo)性穩(wěn)定細(xì)胞株： PrimCells建立的*的誘導(dǎo)性細(xì)胞高效開發(fā)系統(tǒng)，能在極短時(shí)間內(nèi)篩選出低泄漏，高誘導(dǎo)性的穩(wěn)定細(xì)胞株，成功開發(fā)出一系列核受體誘導(dǎo)表達(dá)的穩(wěn)定細(xì)胞株產(chǎn)品，為多家制藥公司研發(fā)部門和科研院所提供產(chǎn)品與服務(wù)，廣受用戶好評(píng)。針對(duì)客戶的特定需求，PrimCells亦提供量身定制服務(wù)，通過(guò)密切的客戶交流和高效的篩選體系，嚴(yán)格保證客戶在3-4周內(nèi)即獲得高質(zhì)量的誘導(dǎo)性穩(wěn)定細(xì)胞株，具有市場(chǎng)其他供應(yīng)商*的時(shí)效性。

美國(guó)人Glucocorticoid糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株（線粒體表達(dá)）

Introduction:

Nuclear hormone receptors (NHRs) are a superfamily of transcription factors that function as powerful metabolic regulators to control a variety of systemic processes in physiology. They also play key roles in the pathophysiology of many major disease states, such as diabetes, obesity, inflammation, atherosclerosis and heart failure. To date, this superfamily has provided a rich source of drug design targets and it is continuing to be one of the hottest areas for pharmaceutical research.

PrimCells now provides a comprehensive set of NHR expressing cell lines to the research community. These high-quality, Flag and/or HA-tagged NHR-expressing cell lines aim to facilitate further biochemical and molecular studies of their functions and hence encourage new strategies for drug design.

Glucocorticoids (GCs) are steroid hormones that allow us to cope with environmental and physiological stresses. Although GCs are widely used as anti-inflammatory agents in several clinical areas, long-term use of those steroids causes problems instead. Full achievement of the clinical potential of GCs necessitates limiting the side effects of these drugs.

The lipophilic nature of GCs allows them to readily diffuse into the cells, where they bind to a cytosolic receptor, the Glucocorticoid Recetpor (GR) to exert their mechanism of action. Without ligand binding, GR is predominantly localized in cytoplasm, whereas upon ligand binding it rapidly translocates to nucleus where it can both positively and negatively regulate gene expression. GR belongs to the nuclear receptor superfamily of ligand-activated transcription factors that function as powerful metabolic regulators. Several studies have shown that GR also translocates to the mitochondrial in addition to its nuclear translocation in response to GC treatment. The mitochondrial GR translocation has been shown to be positively correlated with GC-induced apoptosis, although the mechanism is unclear.

The mitochondrial-specific GR (Flag and HA tagged)/HEK293 cell line was created by stable transfection of HEK293 cells with a plasmid expressing Flag and HA tagged GR protein with a mitochondrial localization signal.

美國(guó)人糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株

美國(guó)PrimCells品牌介紹

PrimCells是位于美國(guó)加州圣迭戈的一家專業(yè)致力于細(xì)胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)。

公司匯集了*的生物醫(yī)藥技術(shù)專家，獨(dú)立開發(fā)了多項(xiàng)原代細(xì)胞和干細(xì)胞相關(guān)的專有技術(shù)。公司以“細(xì)胞研究的優(yōu)選擇"為宗旨，自主研發(fā)超過(guò)70種創(chuàng)新產(chǎn)品，多個(gè)特種細(xì)胞市場(chǎng)的空白。例如其誘導(dǎo)性表達(dá)細(xì)胞庫(kù)和高效3D皮膚培養(yǎng)系統(tǒng)，皆為該類產(chǎn)品目前市場(chǎng)上少數(shù)的規(guī)模化供應(yīng)商。此外，公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項(xiàng)目完成時(shí)間，長(zhǎng)期為多家制藥公司提供解決方案，獲得用戶廣泛贊譽(yù)。

PrimCells產(chǎn)品線：

報(bào)告基因干細(xì)胞 2. 原代細(xì)胞（含報(bào)告基因原代細(xì)胞） 3. 誘導(dǎo)性穩(wěn)定細(xì)胞株

4. 人源重組蛋白 5. 創(chuàng)新型培養(yǎng)試劑

PrimCells 解決方案

1.誘導(dǎo)性穩(wěn)定細(xì)胞株開發(fā) 2. 原代細(xì)胞開發(fā) 3. 藥物體外毒理和效能測(cè)試 4. 3D-皮膚培養(yǎng)

PrimCells合作伙伴及客戶:

A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(lái)(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門

B．科研機(jī)構(gòu)：冷泉港實(shí)驗(yàn)室，哈佛醫(yī)學(xué)院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等

美國(guó)人Glucocorticoid糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株（線粒體表達(dá)）

產(chǎn)品咨詢

留言框

產(chǎn)品：
您的單位：
您的姓名：
聯(lián)系電話：
常用郵箱：
省份：
詳細(xì)地址：
補(bǔ)充說(shuō)明：
驗(yàn)證碼：

請(qǐng)輸入計(jì)算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

美國(guó)人糖皮質(zhì)激素受體穩(wěn)定細(xì)胞株

留言框

產(chǎn)品：

您的單位：

您的姓名：

聯(lián)系電話：

常用郵箱：

省份：

詳細(xì)地址：

補(bǔ)充說(shuō)明：

驗(yàn)證碼：